Chemical formula: C₂₀H₃₀BrNO₃ Molecular mass: 332.463 g/mol PubChem compound: 657308
Ipratropium is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Ipratropium is indicated for treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD).
Ipratropium is indicated, when used concomitantly with inhaled beta2-agonists, for treatment of reversible airways obstruction as in acute and chronic asthma.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Ipratropium is indicated, when used concomitantly with inhaled beta2-agonists, for treatment of reversible airways obstruction as in acute and chronic asthma.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
